12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Company News  |  Other News

XenoPort, GlaxoSmithKline neurology news

GlaxoSmithKline filed suit in the U.S. District Court for the District of Delaware asking for a declaratory judgment that it has fulfilled its contractual obligations under a deal with XenoPort for Horizant gabapentin enacarbil. GSK, which launched the product last year in the U.S. for restless legs syndrome (RLS), claims it exercised "commercially reasonable efforts"...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >